Chigusa Morizane

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. ncbi request reprint Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy
    Hirokazu Shoji
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 44:324-30. 2014
  2. doi request reprint Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 69:957-64. 2012
  3. doi request reprint A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 63:313-9. 2009
  4. doi request reprint Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma
    Chigusa Morizane
    National Cancer Center Hospital, Tokyo, Japan
    Pancreas 40:415-21. 2011
  5. ncbi request reprint A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 69:421-7. 2005
  6. doi request reprint Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805)
    Atsuo Takashima
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 40:1189-91. 2010
  7. ncbi request reprint Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:515-20. 2007
  8. ncbi request reprint Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
    Atsushi Hagihara
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan Department of Hepatology, Osaka City University Hospital, Osaka, Japan
    Cancer Sci 105:354-8. 2014
  9. doi request reprint Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases
    Eiichiro Suzuki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 79:39-45. 2010
  10. pmc Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis
    Hiroshi Mayahara
    Division of Radiation Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo 104 0045, Japan
    BMC Cancer 12:609. 2012

Detail Information

Publications60

  1. ncbi request reprint Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy
    Hirokazu Shoji
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 44:324-30. 2014
    ..The aim of the present study was to clarify the treatment outcome of systemic chemotherapy in patients with advanced ampullary adenocarcinoma...
  2. doi request reprint Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 69:957-64. 2012
    ..We conducted the phase I/II of FDR-Gem and S-1 (FGS) in patients with Gem-refractory PC...
  3. doi request reprint A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 63:313-9. 2009
    ..5% in chemo-naïve patients with pancreatic cancer. This study evaluated the efficacy and toxicity of S-1 in patients with gemcitabine-refractory metastatic pancreatic cancer...
  4. doi request reprint Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma
    Chigusa Morizane
    National Cancer Center Hospital, Tokyo, Japan
    Pancreas 40:415-21. 2011
    ..To identify prognostic factors in patients with metastatic pancreatic adenocarcinoma...
  5. ncbi request reprint A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 69:421-7. 2005
    ..The aim of this study was to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) of combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer...
  6. doi request reprint Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805)
    Atsuo Takashima
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 40:1189-91. 2010
    ..The primary endpoint is the proportion of 1-year overall survival, and the secondary endpoints are progression-free survival, response rate and adverse events...
  7. ncbi request reprint Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:515-20. 2007
    ..The objectives of this study were to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and cisplatin in patients with metastatic pancreatic cancer...
  8. ncbi request reprint Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
    Atsushi Hagihara
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan Department of Hepatology, Osaka City University Hospital, Osaka, Japan
    Cancer Sci 105:354-8. 2014
    ..A randomized phase II trial of sorafenib alone versus sorafenib plus TAI of cisplatin is currently underway. This study was registered at UMIN as trial number UMIN000001496...
  9. doi request reprint Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases
    Eiichiro Suzuki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 79:39-45. 2010
    ..The purpose of this study was to elucidate the treatment efficacy and safety of gemcitabine monotherapy, and to identify prognostic factors in patients with advanced biliary tract cancer receiving this therapy...
  10. pmc Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis
    Hiroshi Mayahara
    Division of Radiation Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo 104 0045, Japan
    BMC Cancer 12:609. 2012
    ..The primary objective of this study was to evaluate the efficacy and safety of salvage CRT after primary chemotherapy for LAPC...
  11. doi request reprint Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites
    Atsuko Soeda
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji Chuo ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 40:1184-8. 2010
    ..Therefore, we need to monitor patients for late-onset, severe and long-lasting skin reactions at injection sites in Wilms tumor-1 cancer vaccine therapy, particularly for combination treatment with gemcitabine...
  12. doi request reprint Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas
    Satoru Iwasa
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Jpn J Clin Oncol 40:313-8. 2010
    ..However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites...
  13. doi request reprint Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacokinet 49:549-58. 2010
    ..The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients...
  14. doi request reprint Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:675-82. 2008
    ..The aim of this study was to identify factors that could be used to predict outcome and tumor response to systemic chemotherapy in patients with metastatic HCC...
  15. doi request reprint Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer
    Miho Kaida
    Department of Medical Oncology, National Cancer Research Center Hospital, Chuo Ku, Tokyo, Japan
    J Immunother 34:92-9. 2011
    ..Although objective clinical efficacy was not apparent, the safety of WT1 vaccine and GEM combination therapy was confirmed in this study...
  16. doi request reprint Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Satoru Iwasa
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 41:770-5. 2011
    ....
  17. ncbi request reprint Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC)
    Yoriko Takezako
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Hepatogastroenterology 55:1380-4. 2008
    ..To clarify the efficacy and toxicity of cisplatin, epirubicin, and continuous infusion of 5-FU (CEF therapy) in patients with advanced intrahepatic cholangiocellular carcinoma (ICC)...
  18. ncbi request reprint [5 -fluoropyrimidines for treatment of biliary tract cancers]
    Chigusa Morizane
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Rinsho 64:529-33. 2006
  19. doi request reprint Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy
    Tsutomu Tanaka
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:755-61. 2008
    ..The purpose of the retrospective analysis is to elucidate the treatment efficacy and toxicity as well as to identify prognostic factors in Japanese patients with advanced pancreatic cancer treated with gemcitabine...
  20. ncbi request reprint [Non-surgical treatment for pancreatic cancer]
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Shokakibyo Gakkai Zasshi 103:391-7. 2006
  21. ncbi request reprint Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 72:188-93. 2007
    ..The objective of this study was to evaluate the antitumor, survival, and adverse effects of hepatic arterial infusion chemotherapy using epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis...
  22. doi request reprint Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
    Kenji Hashimoto
    National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division, Tokyo, Japan
    Oncology 77:217-23. 2009
    ..Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial...
  23. ncbi request reprint [S-1 monotherapy for pancreatic cancer]
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Gan To Kagaku Ryoho 33:207-12. 2006
    ..S-1 is active and well tolerated in patients with metastatic pancreatic cancer. Randomized trials are warranted to determine the effectiveness of S-1 for the treatment of pancreatic cancer...
  24. doi request reprint Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)
    Chigusa Morizane
    Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 104:1211-6. 2013
    ..This study was registered at the UMIN Clinical Trials Registry as UMIN 000001685 (http://www.umin.ac.jp/ctr/index.htm)...
  25. doi request reprint Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy
    Tomoko Katsui Taniyama
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Pancreatology 12:428-33. 2012
    ..A global consensus on how to treat recurrent pancreatic cancer after adjuvant chemotherapy with gemcitabine (ADJ-GEM) does not exist...
  26. ncbi request reprint A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 35:439-43. 2005
    ..However, its activity in biliary tract carcinoma has not been fully evaluated. The aim of this study was to evaluate the antitumor activity and toxicity of UFT in chemotherapy-naive patients with advanced biliary tract carcinoma...
  27. ncbi request reprint Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients
    Chigusa Morizane
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 68:432-7. 2005
    ..This study investigated the outcome and tolerability of this treatment in elderly patients...
  28. doi request reprint Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent
    Yoshitaka Seki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 39:751-5. 2009
    ..Prospective clinical trials are necessary to confirm the effectiveness of fluoropyrimidine for the treatment of pancreatic ACC...
  29. doi request reprint Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas
    Taiga Otsuka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Pancreas 42:889-92. 2013
    ....
  30. ncbi request reprint [Chemotherapy]
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Gan To Kagaku Ryoho 37:408-12. 2010
    ..After the introduction of sorafenib, chemotherapy for advanced hepatocellular carcinoma has been changing remarkably, and further improvements of chemotherapy for hepatocellular carcinoma are expected...
  31. ncbi request reprint An early phase II study of S-1 in patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Oncology 68:171-8. 2005
    ..The aim of this study was to evaluate the efficacy and toxicity of S-1 in patients with metastatic pancreatic cancer...
  32. doi request reprint Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
    Shunsuke Kondo
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 18:207-13. 2013
    ..We evaluated c-Met protein expression and its gene amplification in order to assess whether they were related to tumor recurrence and survival rates among patients who had undergone tumor resection...
  33. ncbi request reprint A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization
    Tsutomu Tanaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Cancer Chemother Pharmacol 61:683-8. 2008
    ..The aim of this study was to evaluate the antitumor activity and toxicity of transcatheter arterial infusion chemotherapy using an epirubicin-Lipiodol emulsion in patients with TAE-refractory HCC...
  34. ncbi request reprint Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma
    Kazuaki Shimada
    Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
    Ann Surg Oncol 14:2337-47. 2007
    ..In addition, selections of the most effective treatments for patients with recurrent HCC still remain controversial...
  35. ncbi request reprint [Hepatocellular carcinoma]
    Shunsuke Kondo
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Gan To Kagaku Ryoho 37:1219-23. 2010
    ..Systemic chemotherapy for hepatocellular carcinoma has been greatly advancing, and further improvements of chemotherapy in hepatocellular carcinoma are expected...
  36. ncbi request reprint Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy
    Toshimitsu Saisho
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Hepatogastroenterology 52:1654-8. 2005
    ..Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy have not been fully examined. This study investigated prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy...
  37. doi request reprint Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 103:1524-30. 2012
    ..5%. In conclusion, the recommended dose of TAC-101 for patients with HCC is 20 mg/day. TAC-101 had an acceptable toxicity profile, warranting further evaluation in clinical trials...
  38. ncbi request reprint FP therapy for controlling malignant ascites in advanced pancreatic cancer patients
    Kan Yonemori
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Hepatogastroenterology 54:2383-6. 2007
    ..We conducted a retrospective analysis to evaluate the efficacy of 5-fluorouracil (5-FU) plus cisplatin (FP therapy) for controlling malignant ascites in patients with advanced pancreatic cancer...
  39. ncbi request reprint Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK)
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 23:379-84. 2008
    ..Our findings suggest considerable ethnic differences in genetic variations of DCK and provide fundamental and useful information for genotyping DCK in the Japanese and probably other Asian populations...
  40. doi request reprint A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1
    Chigusa Morizane
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:973. 2007
  41. ncbi request reprint A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer 103:756-62. 2005
    ....
  42. doi request reprint Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases
    Atsushi Naganuma
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 42:640-5. 2012
    ..To our knowledge, this is the first report to provide evidence that strontium-89 can be useful in controlling intractable hypoglycemia in patients with malignant insulinoma with bone metastases...
  43. doi request reprint Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer
    Hidenori Kido
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 42:845-50. 2012
    ..Thus, it is speculated that the pericardial effusion and bilateral pleural effusion may have been caused by gemcitabine...
  44. ncbi request reprint [Palliative therapy in patients with biliary tract cancer]
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Rinsho 64:565-7. 2006
  45. doi request reprint Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications
    Junichi Matsubara
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo, 104 0045, Japan
    J Gastroenterol 43:225-32. 2008
    ....
  46. ncbi request reprint Spontaneous regression of hepatocellular carcinoma
    Shunsuke Kondo
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 11:407-11. 2006
    ..Another showed spontaneous regression after taking several complementary and alternative medicines. However, the mechanisms underlying this intriguing phenomenon remain unknown...
  47. ncbi request reprint Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    J Gastroenterol 49:932-40. 2014
    ....
  48. ncbi request reprint Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
    Masafumi Ikeda
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Cancer Sci 105:455-62. 2014
    ..Furthermore, three patients showed long-term stable disease of more than 5 months. In conclusion, GC33 given at up to 20 mg/kg weekly was well tolerated in Japanese patients with advanced hepatocellular carcinoma...
  49. pmc Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
    Shunsuke Kondo
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    BMC Cancer 12:268. 2012
    ....
  50. doi request reprint Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: report of a case
    Satoshi Nara
    Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Surg Today 38:271-4. 2008
    ..Unnecessary surgical intervention was avoided by an early and accurate diagnosis and effective antifungal therapy. The bile culture was the key to the definitive diagnosis in this case...
  51. doi request reprint Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer
    Atsuko Soeda
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 39:797-806. 2009
    ..This study was designed to evaluate the immunological reaction by gemcitabine for future clinical trial of combination therapy with gemcitabine and cancer vaccines...
  52. doi request reprint His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk
    Shumpei Ohnami
    Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    Gastroenterology 135:477-88. 2008
    ..This study attempts to elucidate a part of the genetic predisposition to the sporadic invasive ductal adenocarcinoma of the pancreas focusing on the genes implicated in the gene-environment interactions in carcinogenesis...
  53. doi request reprint Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine
    Makiko Ono
    Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Gastric Cancer 11:201-5. 2008
    ..Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis. Treatment strategies for SBA have not been clearly established...
  54. pmc Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
    Satoshi Shiba
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Case Rep Oncol 5:515-9. 2012
    ..This is the first report describing HBV reactivation with an increasing HBV-DNA level in a HBsAg-negative/HBcAb-positive/HBsAb-positive patient who was treated with TSU-68 for hepatocellular carcinoma...
  55. ncbi request reprint Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 35:733-8. 2005
    ..The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m(2)/min) on a weekly schedule to Japanese patients with unresectable advanced pancreatic cancer...
  56. ncbi request reprint Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Junji Furuse
    National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:552-6. 2006
    ..The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer...
  57. doi request reprint Emerging drugs for biliary cancer
    Takuji Okusaka
    National Cancer Center Hospital, Department of Hepatobiliary and Pancreatic Oncology, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan 81 3 3542 2511 81 3 3542 3815
    Expert Opin Emerg Drugs 19:11-24. 2014
    ....
  58. ncbi request reprint [Tumor markers for pancreatic and biliary tract cancer]
    Yoriko Takezako
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Gan To Kagaku Ryoho 31:1443-6. 2004
    ..Therefore, improvements in survival may well result from screening for early-stage pancreatic and biliary cancer. The development of tumor markers with higher sensitivity and specificity should have the highest priority...
  59. doi request reprint Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333
    Takuji Okusaka
    National Cancer Center Hospital, Tokyo National Cancer Center East Hospital, Kashiwa City, Chiba, Japan
    Hepatol Res 41:542-52. 2011
    ..Conclusion:  Hypertension was noted as a DLT at the dose level of 900 mg/day, and this dose was considered to be inappropriate. The recommended dose for the phase II/III clinical trial is thought to be 300 mg/day and 600 mg/day...
  60. doi request reprint A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Department of Gastroenterology, University of Tokyo, Tokyo, Japan
    Cancer Chemother Pharmacol 67:315-24. 2011
    ....